Come up with a name for your new list and we'll add to it:
PhosImmune raised a round of funding on August 12, 2014. Investors include
CIT GAP Funds.
PhosImmune is a cancer immunotherapy company that was founded to commercialize a library of phosphopeptide tumor targets (PTTs) discovered at the University of Virginia and the University of Birmingha…